- IP hearings this week
- IP trials
- IP Judicial review hearings
- IP appeals at the Federal Court of Appeal
(As published on the Federal Court and Federal Court of Appeal websites on Aug 5, 2026)
This week in IP
| Date | File No. | Type | Name | Location | Length |
| Aug 13, 2026 | T-1257-22 | CMC | Bell Media Inc Et Al. V. Marshall Macciacchera Et Al (Copyright) | Toronto | 45 m |
| Aug 14, 2026 | T-3922-25 | M | Astrazeneca Canada Inc. Et Al. V. Natco Pharma (canada) Inc. (Patent - Olaparib*) | Toronto | 1 d |
| Aug 17, 2026 | T-3013-24 | JR | Faisal Anashara V. Bizu Innovation Group (Trade Mark - JR) | Toronto | 1 h |
| Aug 17, 2026 | T-7-25 | T | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 5 d |
| Aug 17, 2026 | T-8-25 | T | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 5 d |
| Aug 17, 2026 | T-9-25 | T | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 5 d |
| Aug 17, 2026 | T-3381-25 | CMC | Maxunitech North America, Inc. Et Al. V. Sharda Cropchem Limited (Patent) | Toronto | 1 h |
| Aug 17, 2026 | T-5200-25 | CMC | Astrazeneca Canada Inc. Et Al. V. Zydus Lifesciences Limited (Patent - Olaparib*) | Toronto | 1 h |
| Aug 17, 2026 | T-703-20 | CMC | Kaira District Coop Milk Producers Union Ltd Et Al. V Amul Canada Ltd Et Al. (Trade Mark) | Toronto | 1 h |
| Aug 18, 2026 | T-2055-25 | M | Niagara River Trading Company Inc. V. A & D Fiesta Inc. (unknown) | Ottawa | 2 h |
| Aug 18, 2026 | T-2576-23 | CMC | Oakville Stamping & Bending Limited V. Jean-louis Cloutier , Dba Ontario Sol (Patent) | Ottawa | 1 h |
| Aug 19, 2026 | T-2180-24 | M | Veracio Canada Ltd. Et Al. V. Geologicai Inc. Et Al. (Patent) | Ottawa | 1 d |
| Aug 19, 2026 | T-451-20 | CMC | Kobold Corporation Et Al. V. Ncs Multistage Inc. (Patent) | Toronto | 30 m |
| Aug 19, 2026 | T-669-25 | TMC | Brar Natural Flour Milling Inc V First Choice Foods Inc. (Trade Mark) | Toronto | 1 h |
Return to top.
Scheduled IP Trials
| Date | File No. | Name | Location | Length |
| Aug 17, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 5 d |
| Aug 17, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 5 d |
| Aug 17, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 5 d |
| Aug 24, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 5 d |
| Aug 24, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 5 d |
| Aug 24, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 5 d |
| Aug 31, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 5 d |
| Aug 31, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 5 d |
| Aug 31, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 5 d |
| Sep 8, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 2 d |
| Sep 8, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 2 d |
| Sep 8, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 2 d |
| Sep 8, 2026 | T-1142-18 | Navtech Inc. V. Chantier Davie Canada Inc. (unknown) | Québec | 4 d |
| Sep 14, 2026 | T-1567-24 | Justin Stitches Inc. V. Makers Holdings Inc. (Trade Mark) | Vancouver | 5 d |
| Sep 16, 2026 | T-1142-18 | Navtech Inc. V. Chantier Davie Canada Inc. (unknown) | Québec | 2 d |
| Sep 24, 2026 | T-7-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada (Patent - Apalutamide*) | Toronto | 2 d |
| Sep 24, 2026 | T-8-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 2 d |
| Sep 24, 2026 | T-9-25 | Aragon Pharmaceuticals, Inc. Et Al. V. Sandoz Canada Inc. (Patent - Apalutamide*) | Toronto | 2 d |
| Oct 19, 2026 | T-451-20 | Kobold Corporation Et Al. V. Ncs Multistage Inc. (Patent) | Calgary | 4 d |
| Oct 19, 2026 | T-1059-22 | Seylynn (north Shore) Development Limited Partnership V. Denna Homes Group (Trade Mark) | Vancouver | 10 d |
| Oct 26, 2026 | T-451-20 | Kobold Corporation Et Al. V. Ncs Multistage Inc. (Patent) | Calgary | 4 d |
| Nov 4, 2026 | T-1059-22 | Seylynn (north Shore) Development Limited Partnership V. Denna Homes Group (Trade Mark) | Vancouver | 2 d |
| Nov 9, 2026 | T-2593-24 | Janssen Inc. Et Al. V. Pharmascience Inc. (Patent - Macitentan*) | Toronto | 2 d |
| Nov 12, 2026 | T-2593-24 | Janssen Inc. Et Al. V. Pharmascience Inc. (Patent - Macitentan*) | Toronto | 2 d |
| Nov 18, 2026 | T-451-20 | Kobold Corporation Et Al. V. Ncs Multistage Inc. (Patent) | Calgary | 2 d |
| Nov 23, 2026 | T-742-25 | Salix Pharmaceuticals, Inc. V. Sandoz Canada Inc. (Patent) | Toronto | 8 d |
| Dec 7, 2026 | T-742-25 | Salix Pharmaceuticals, Inc. V. Sandoz Canada Inc. (Patent) | Toronto | 2 d |
| Jan 18, 2027 | T-1792-21 | Tanja Porcnik V. Cato Institute Et Al. (Copyright) | Toronto | 4 d |
| Jan 25, 2027 | T-1792-21 | Tanja Porcnik V. Cato Institute Et Al. (Copyright) | Toronto | 4 d |
| Feb 3, 2027 | T-1792-21 | Tanja Porcnik V. Cato Institute Et Al. (Copyright) | Toronto | 2 d |
| Mar 10, 2027 | T-2504-25 | Novartis Pharmaceuticals Canada Inc Et Al. V. Apotex Inc. (Patent) | To be determined (TrialJA) | 10 d |
| Mar 10, 2027 | T-2505-25 | Novartis Pharmaceuticals Canada Inc Et Al. V. Apotex Inc. (Patent - Trametinib*) | To be determined (TrialJA) | 10 d |
| Mar 30, 2027 | T-2505-25 | Novartis Pharmaceuticals Canada Inc Et Al. V. Apotex Inc. (Patent - Trametinib*) | To be determined (TrialJA) | 2 d |
| Mar 30, 2027 | T-2504-25 | Novartis Pharmaceuticals Canada Inc Et Al. V. Apotex Inc. (Patent) | To be determined (TrialJA) | 2 d |
| Apr 19, 2027 | T-3096-25 | Astrazeneca Canada Inc. Et Al. V. Cipla Ltd. (Patent - Olaparib*) | To be determined (TrialJA) | 4 d |
| Apr 26, 2027 | T-3096-25 | Astrazeneca Canada Inc. Et Al. V. Cipla Ltd. (Patent - Olaparib*) | To be determined (TrialJA) | 4 d |
| May 10, 2027 | T-3206-25 | Leo Pharma Inc. Et Al. V. Glenmark Pharmaceuticals Canada Inc. (Patent - Calcipotriol*) | Toronto | 4 d |
| May 10, 2027 | T-3096-25 | Astrazeneca Canada Inc. Et Al. V. Cipla Ltd. (Patent - Olaparib*) | To be determined (TrialJA) | 2 d |
| May 17, 2027 | T-3206-25 | Leo Pharma Inc. Et Al. V. Glenmark Pharmaceuticals Canada Inc. (Patent - Calcipotriol*) | Toronto | 3 d |
| May 25, 2027 | T-3206-25 | Leo Pharma Inc. Et Al. V. Glenmark Pharmaceuticals Canada Inc. (Patent - Calcipotriol*) | Toronto | 2 d |
| Jun 22, 2027 | T-3922-25 | Astrazeneca Canada Inc. Et Al. V. Natco Pharma (canada) Inc. (Patent - Olaparib*) | Ottawa | 9 d |
| Jun 28, 2027 | T-3739-25 | Novartis Pharmaceuticals Canada Inc V. Pharmascience Inc. Et Al. (Patent - Ruxolitinib*) | To be determined (TrialJA) | 3 d |
| Jul 2, 2027 | T-3739-25 | Novartis Pharmaceuticals Canada Inc V. Pharmascience Inc. Et Al. (Patent - Ruxolitinib*) | To be determined (TrialJA) | 5 d |
| Jul 7, 2027 | T-3922-25 | Astrazeneca Canada Inc. Et Al. V. Natco Pharma (canada) Inc. (Patent - Olaparib*) | Ottawa | 2 d |
| Jul 15, 2027 | T-3739-25 | Novartis Pharmaceuticals Canada Inc V. Pharmascience Inc. Et Al. (Patent - Ruxolitinib*) | To be determined (TrialJA) | 2 d |
| Aug 9, 2027 | T-4459-25 | Novartis Pharmaceuticals Canada Inc. V. Dr. Reddy's Laboratories Ltd. Et Al. (Patent - Ruxolitinib*) | Ottawa | 10 d |
| Aug 26, 2027 | T-4459-25 | Novartis Pharmaceuticals Canada Inc. V. Dr. Reddy's Laboratories Ltd. Et Al. (Patent - Ruxolitinib*) | Ottawa | 2 d |
| Sep 7, 2027 | T-116-19 | Unilin Beheer B.v. Et Al V. 6035558 Canada Inc. Et Al (Patent) | Toronto | 4 d |
| Sep 7, 2027 | T-1742-23 | Dermaspark Products Inc. Et Al. V. Dynamite Beauty Academy Ltd Et Al. (Trade Mark) | Vancouver | 4 d |
| Sep 13, 2027 | T-1742-23 | Dermaspark Products Inc. Et Al. V. Dynamite Beauty Academy Ltd Et Al. (Trade Mark) | Vancouver | 2.3 d |
| Sep 13, 2027 | T-116-19 | Unilin Beheer B.v. Et Al V. 6035558 Canada Inc. Et Al (Patent) | Toronto | 4 d |
| Sep 20, 2027 | T-116-19 | Unilin Beheer B.v. Et Al V. 6035558 Canada Inc. Et Al (Patent) | Toronto | 4 d |
| Oct 4, 2027 | T-116-19 | Unilin Beheer B.v. Et Al V. 6035558 Canada Inc. Et Al (Patent) | Toronto | 2 d |
| Oct 19, 2027 | T-846-26 | Novartis Pharmaceuticals Canada Inc. Et Al. V. Zydus Lifesciences Limited (Patent - Sacubitril*) | Ottawa | 8 d |
| Nov 8, 2027 | T-323-26 | Lundbeck Canada Inc. Et Al. V. Laboratoire Riva Inc. (Patent - Vortioxetine*) | To be determined (TrialJA) | 10 d |
| Nov 22, 2027 | T-1545-26 | Taiho Pharmaceutical Co., Ltd Et Al. V. Natco Pharma (canada) Inc. (Patent - Trifluridine*) | Toronto | 4 d |
| Nov 22, 2027 | T-1266-26 | Genentech, Inc. And Hoffmann-la Roche Limtited V. Biosimilar Collaborations Ireland Limited (Patent) | Toronto | 4 d |
| Nov 24, 2027 | T-323-26 | Lundbeck Canada Inc. Et Al. V. Laboratoire Riva Inc. (Patent - Vortioxetine*) | To be determined (TrialJA) | 2 d |
| Nov 29, 2027 | T-1545-26 | Taiho Pharmaceutical Co., Ltd Et Al. V. Natco Pharma (canada) Inc. (Patent - Trifluridine*) | Toronto | 4 d |
| Nov 29, 2027 | T-1266-26 | Genentech, Inc. And Hoffmann-la Roche Limtited V. Biosimilar Collaborations Ireland Limited (Patent) | Toronto | 4 d |
| Dec 6, 2027 | T-1545-26 | Taiho Pharmaceutical Co., Ltd Et Al. V. Natco Pharma (canada) Inc. (Patent - Trifluridine*) | Toronto | 5 d |
| Dec 7, 2027 | T-1266-26 | Genentech, Inc. And Hoffmann-la Roche Limtited V. Biosimilar Collaborations Ireland Limited (Patent) | Toronto | 2 d |
| Dec 16, 2027 | T-1545-26 | Taiho Pharmaceutical Co., Ltd Et Al. V. Natco Pharma (canada) Inc. (Patent - Trifluridine*) | Ottawa | 2 d |
| Jan 10, 2028 | T-3901-25 | Verifi Llc V. Giatec Scientific Inc. (Patent) | Ottawa | 4 d |
| Jan 10, 2028 | T-2038-26 | Vertex Pharmaceuticals (canada) Inc. Et Al. V. Jamp Pharma Corp. (Patent - Ivacaftor*) | Toronto | 9 d |
| Jan 17, 2028 | T-3901-25 | Verifi Llc V. Giatec Scientific Inc. (Patent) | Ottawa | 4 d |
| Jan 24, 2028 | T-2043-26 | Astellas Pharma Canada Inc. Et Al. V. Mint Pharmaceuticals Inc. (Patent - Mirabegron*) | Toronto | 4 d |
| Jan 24, 2028 | T-3901-25 | Verifi Llc V. Giatec Scientific Inc. (Patent) | Ottawa | 5 d |
| Jan 26, 2028 | T-2038-26 | Vertex Pharmaceuticals (canada) Inc. Et Al. V. Jamp Pharma Corp. (Patent - Ivacaftor*) | Toronto | 1 d |
| Jan 31, 2028 | T-2043-26 | Astellas Pharma Canada Inc. Et Al. V. Mint Pharmaceuticals Inc. (Patent - Mirabegron*) | Toronto | 4 d |
| Feb 3, 2028 | T-3901-25 | Verifi Llc V. Giatec Scientific Inc. (Patent) | Ottawa | 2 d |
| Feb 9, 2028 | T-2043-26 | Astellas Pharma Canada Inc. Et Al. V. Mint Pharmaceuticals Inc. (Patent - Mirabegron*) | Toronto | 2 d |
| Feb 14, 2028 | T-2548-26 | Salix Pharmaceuticals Inc. V. Apotex Inc. (Patent) | Toronto | 7 d |
| Feb 22, 2028 | T-2838-26 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Ascend Laboratories Ltd. (Patent - Empagliflozin*) | To be determined (TrialJA) | 8 d |
| Feb 24, 2028 | T-2548-26 | Salix Pharmaceuticals Inc. V. Apotex Inc. (Patent) | Ottawa | 2 d |
| Mar 8, 2028 | T-2838-26 | Boehringer Ingelheim (canada) Ltd. Et Al. V. Ascend Laboratories Ltd. (Patent - Empagliflozin*) | To be determined (TrialJA) | 2 d |
Return to top.
Scheduled Judicial Review Hearings
| Date | File No. | Name | Type | Location | Length |
| Aug 17, 2026 | T-3013-24 | Faisal Anashara V. Bizu Innovation Group | Trade Mark Expungement | Toronto | 1 h |
| Sep 1, 2026 | T-3647-25 | Lion Corporation V. Mbm Intellectual Property Agency | Trade Mark - Appeal of a decision of the Registrar | Ottawa | 3 h |
| Oct 5, 2026 | T-5157-25 | Engineers Canada / Ingã©nieurs Canada V. Enginia Srl | Trade Mark - Appeal of a decision of the Registrar | Ottawa | 1 d |
| Oct 26, 2026 | T-3686-25 | Surya Foods Limited V. Bhupinder Dhanju | Trade Mark Expungement | Vancouver | 1 d |
Return to top.
Scheduled IP Appeals
| Date | File No. | Name | Type | Location |
| Sep 9, 2026 | A-347-23 | Abbvie Corporation Et Al V. Jamp Pharma Corporation | Appeal (S.27 - Final) - Patent Act | Toronto |
| Sep 9, 2026 | A-348-23 | Abbvie Corporation And Abbvie Biotechnology Ltd V. Jamp Pharma Corp. - Adalimumab* | Appeal (S.27 - Interloc.) - Patent Act [from T-561-21 - Patented Medicines (NOC) Regulations [Actions]] | Toronto |
| Oct 1, 2026 | A-188-25 | Itp Sa V. Cnooc Petroleum North America Ulc | Appeal (S.27 - Final) - Copyright Act [from T-2563-23 - Copyright Infringement [Applications]] | Toronto |
* Medicinal ingredients are based on automated analysis and should not be relied upon.
Return to top.